ArticleCancer chemotherapy and pharmacology2022

Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer.

Jeffrey R Proctor et al.PubMed ↗Publisher ↗

No numbers read from the abstract.